A view on EGFR-targeted therapies from the oncogene-addiction perspective

Frontiers in Pharmacology

Volumn 4 APR, Issue , 2013, Pages

  Perez, Rolando ^a,b   Crombet, Tania ^a   de Leon, Joel ^a   Moreno, Ernesto ^a,b  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

^b Biotech Pharmaceuticals Co Ltd   (China)

Author keywords

Cetuximab; Combination therapy; EGFR; Erlotinib; Nimotuzumab; Oncogene addiction; Targeted therapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MICRORNA; MICRORNA 128B; NIMOTUZUMAB; OXALIPLATIN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PLATINUM DERIVATIVE; PROTEIN KINASE B; SODIUM GLUCOSE COTRANSPORTER 1; UNCLASSIFIED DRUG;

ADVANCED CANCER; ARTICLE; BRAIN TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER STEM CELL; CANCER THERAPY; CELL HYPOXIA; COLORECTAL CANCER; DRUG DOSE ESCALATION; DRUG RESPONSE; EGFR GENE; ESOPHAGUS CANCER; GENE INACTIVATION; GENE OVEREXPRESSION; GLIOMA; GLUCOSE TRANSPORT; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NASOPHARYNX TUMOR; ONCOGENE; ONCOGENE ADDICTION; PANCREAS CANCER; PERSONALIZED MEDICINE; T LYMPHOCYTE; TREATMENT FAILURE; TUMOR CELL; TUMOR IMMUNITY; UNSPECIFIED SIDE EFFECT;

EID: 84881517936     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2013.00053     Document Type: Article

References (85)

1. Abhold, E. L., Kiang, A., Rahimy, E., Kuo, S. Z., Wang-Rodriguez, J., Lopez, J. P., et al. (2012). EGFR kinase promotes acquisition of stem cell-like properties: a potential therapeutic target in head and neck squamous cell carcinoma stem cells. PLoS ONE 7:e32459. doi: 10.1371/journal.pone.0032459
2. Aguiar Alpizar, Y., Karwacz, K., Arce, F., Yglesias Rivera, A., Fernández, L. E., Collins, M. K., et al. (2012). Lentiviral vector followed by protein immunisation breaks tolerance against the self-antigen Her1 and results in lung cancer immunotherapy. J. Gene Med. 14, 151-157.
3. Ayuso-Sacido, A., Moliterno, J. A., Kratovac, S., Kapoor, G. S., O'Rourke, D. M., Holland, E. C., et al. (2010). Activated EGFR signaling increases proliferation, survival, and migration and blocks neuronal differentiation in post-natal neural stem cells. J. Neurooncol. 97, 323-337.
4. Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., et al. (2006). Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756-760.
5. Barnea, I., Haif, S., Keshet, R., Karaush, V., Lev Ari, S., Khafif, A., et al. (2013). Targeting ErbB-1 and ErbB-4 in irradiated head and neck cancer: results of in vitro and in vivo studies. Head Neck 35, 399-407.
6. Basavaraj, C., Sierra, P., Shivu, J., Melarkode, R., Montero, E., and Nair, P. (2010). Nimotuzumab with chemoradiation confers a survival advantage in treatment-naïve head and neck tumors over expressing EGFR. Cancer Biol. Ther. 10, 673-681.
7. Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., et al. (2006). Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354, 567-578.
8. Califano, R., Landi, L., and Cappuzzo, F. (2012). Prognostic and predictive value of K-RAS mutations in non-small cell lung cancer. Drugs 72(Suppl. 1), 28-36.
9. Cappuzzo, F., Ciuleanu, T., Stelmakh, L., Cicenas, S., Szczésna, A., Juhász, E., et al. (2010). Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 11, 521-529.
10. Crombet, T., Osorio, M., Cruz, T., Roca, C., del Castillo, R., Mon, R., et al. (2004). Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J. Clin. Oncol. 22, 1646-1654.
11. Crombet-Ramos, T., Rak, J., Pérez, R., and Viloria-Petit, A. (2002). Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: a humanized anti-EGFR antibody. Int. J. Cancer 101, 567-575.
12. Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., et al. (2004). Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351, 337-345.
13. Del Vecchio, C. A., Jensen, K. C., Nitta, R. T., Shain, A. H., Giacomini, C. P., and Wong, A. J. (2012). Epidermal growth factor receptor variant III contributes to cancer stem cell phenotypes in invasive breast carcinoma. Cancer Res. 72, 2657-2671.
14. Diaz Miqueli, A., Rolff, J., Lemm, M., Fichtner, I., Perez, R., and Montero, E. (2009). Radiosensitization of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies. Br. J. Cancer 100, 950-958.
15. Downward, J., Yarden, Y., Mayes, E., Scrace, G., Totty, N., Stockwell, P., et al. (1984). Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 307, 521-527.
16. Driessens, G., Beck, B., Caauwe, A., Simons, B. D., and Blanpain, C. (2012). Defining the mode of tumour growth by clonal analysis. Nature 488, 527-530.
17. El-Haibi, C. P., Bell, G. W., Zhang, J., Collmann, A. Y., Wood, D., Scherber, C. M., et al. (2012). Critical role for lysyl oxidase in mesenchymal stem cell-driven breast cancer malignancy. Proc. Natl. Acad. Sci. U.S.A. 109, 17460-17465.
18. Engelman, J. A. (2009). Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer 9, 550-562.
19. Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., et al. (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039-1043.
20. Eyler, C. E., Foo, W.-C., LaFiura, K. M., McLendon, R. E., Hjelmeland, A. B., and Rich, J. N. (2008). Brain cancer stem cells display preferential sensitivity to Akt inhibition. Stem Cells 26, 3027-3036.
21. Ferraro, D. A., Gaborit, N., Maron, R., Cohen Dvashi, H., Porat, Z., Pareja, F., et al. (2013). Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR. Proc. Natl. Acad. Sci. U.S.A. 110, 1815-1820.
22. Garrett, J. T., and Arteaga, C. L. (2011). Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications. Cancer Biol. Ther. 11, 793-800.
23. Garrido, G., Lorenzano, P., Sánchez, B., Beausoleil, I., Alonso, D. F., Pérez, R., et al. (2007). T cells are crucial for the anti-metastatic effect of anti-epidermal growth factor receptor antibodies. Cancer Immunol. Immunother. 56, 1701-1710.
24. Garrido, G., Rabasa, A., Sánchez, B., López, M. V., Blanco, R., López, A., et al. (2011a). Induction of immunogenic apoptosis by blockade of epidermal growth factor receptor activation with a specific antibody. J. Immunol. 187, 4954-4966.
25. Garrido, G., Tikhomirov, I. A., Rabasa, A., Yang, E., Gracia, E., Iznaga, N., et al. (2011b). Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile. Cancer Biol. Ther. 11, 373-382.
26. Guarino, M. J., Schneider, C. J., Hosford, M. A., Brahmer, J. R., Rudin, C. M., Finckenstein, F. G., et al. (2009). Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: a phase I study in patients with advanced solid malignancies. Oncologist 14, 119-124.
27. Guo, G. F., Cai, Y. C., Zhang, B., Xu, R. H., Qiu, H. J., Xia, L. P., et al. (2011). Overexpression of SGLT1 and EGFR in colorectal cancer showing a correlation with the prognosis. Med. Oncol. 28(Suppl. 1), S197-S203.
28. Hanabata, Y., Nakajima, Y., Morita, K., Kayamori, K., and Omura, K. (2012). Coexpression of SGLT1 and EGFR is associated with tumor differentiation in oral squamous cell carcinoma. Odontology 100, 156-163.
29. Hardy, K. M., Booth, B. W., Hendrix, M. J. C., Salomon, D. S., and Strizzi, L. (2010). ErbB/EGF signaling and EMT in mammary development and breast cancer. J. Mammary Gland Biol. Neoplasia 15, 191-199.
30. Hendler, F. J., and Ozanne, B. W. (1984). Human squamous cell lung cancers express increased epidermal growth factor receptors. J. Clin. Invest. 74, 647-651.
31. Herbst, R. S., Ansari, R., Bustin, F., Flynn, P., Hart, L., Otterson, G. A., et al. (2011). Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet 377, 1846-1854.
32. Huber, S. M., Misovic, M., Mayer, C., Rodemann, H.-P., and Dittmann, K. (2012). EGFR-mediated stimulation of sodium/glucose cotransport promotes survival of irradiated human A549 lung adenocarcinoma cells. Radiother. Oncol. 103, 373-379.
33. Janjigian, Y. Y., Azzoli, C. G., Krug, L. M., Pereira, L. K., Rizvi, N. A., Pietanza, M. C., et al. (2011). Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. Clin. Cancer Res. 17, 2521-2527.
34. Jedlinski, A., Ansell, A., Johansson, A. C., and Roberg, K. (2013). EGFR status and EGFR ligand expression influence the treatment response of head and neck cancer cell lines. J. Oral Pathol. Med. 42, 26-36.
35. Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., et al. (2007). Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med. 357, 2040-2048.
36. Kabbinavar, F. F., Miller, V. A., Johnson, B. E., O'Connor, P. G., Soh, P. G., and ATLAS Investigators (2010). Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J. Clin. Oncol. 28(Suppl. 15), abstr. 7526.
37. Khambata-Ford, S., Garrett, C. R., Meropol, N. J., Basik, M., Harbison, C. T., Wu, S., et al. (2007). Express- ion of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colo- rectal cancer patients treated with cetuximab. J. Clin. Oncol. 25, 3230-3237.
38. Kim, Y. H., Sasaki, Y., Lee, K. H., Rha, S. Y., Park, S. H., Boku, N., et al. (2011). Randomized phase II study of nimotuzumab, an anti-EGFR antibody, plus irinotecan in patients with 5-fluorouracil-based regimen-refractory advanced or recurrent gastric cancer in Korea and Japan: preliminary results. J. Clin. Oncol. 29(Suppl. 4), abstr. 87.
39. Kroemer, G., and Pouyssegur, J. (2008). Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13, 472-482.
40. Lièvre, A., Bachet, J. B., Le Corre, D., Boige, V., Landi, B., Emile, J. F., et al. (2006). KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66, 3992-3995.
41. Lipson, E. J., and Drake, C. G. (2011). Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin. Cancer Res. 17, 6958-6962.
42. Luedke, E., Jaime-Ramirez, A. C., Bhave, N., Roda, J., Choudhary, M. M., Kumar, B., et al. (2012). Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines. Surgery 152, 431-440.
43. Mantovani, A., Allavena, P., Sica, A., and Balkwill, F. (2008). Cancer-related inflammation. Nature 454, 436-444.
44. Mateo, C., Moreno, E., Amour, K., Lombardero, J., Harris, W., and Pérez, R. (1997). Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity. Immunotechnology 3, 71-81.
45. Mazzoleni, S., Politi, L. S., Pala, M., Cominelli, M., Franzin, A., Sergi Sergi, L., et al. (2010). Epidermal growth factor receptor expression identifies functionally and molecularly distinct tumor-initiating cells in human glioblastoma multiforme and is required for gliomagenesis. Cancer Res. 70, 7500-7513.
46. Montagut, C., Dalmases, A., Bellosillo, B., Crespo, M., Pairet, S., Iglesias, M., et al. (2012). Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer. Nat. Med. 18, 221-223.
47. Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., et al. (2007). Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25, 1960-1966.
48. Nguyen, L. V., Vanner, R., Dirks, P., and Eaves, C. J. (2012). Cancer stem cells: an evolving concept. Nat. Rev. Cancer 12, 133-143.
49. Pander, J., Heusinkveld, M., Van der Straaten, T., Jordanova, E. S., Baak-Pablo, R., Gelderblom, H., et al. (2011). Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab. Clin. Cancer Res. 17, 5668-5673.
50. Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., et al. (2005). Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2:e73. doi: 10.1371/journal.pmed.0020073
51. Perez, R., Moreno, E., Garrido, G., and Crombet, T. (2011). EGFR-targeting as a biological therapy: understanding Nimotuzumab's clinical effects. Cancers 3, 2014-2031.
52. Pérol, M., Chouaid, C., Pérol, D., Barlési, F., Gervais, R., Westeel, V., et al. (2012). Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 30, 3516-3524.
53. Pirker, R., Pereira, J. R., Szczesna, A., Von Pawel, J., Krzakowski, M., Ramlau, R., et al. (2009). Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373, 1525-1531.
54. Pirker, R., Pereira, J. R., Von Pawel, J., Krzakowski, M., Ramlau, R., Park, K., et al. (2012). EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol. 13, 33-42.
55. Quatrale, A. E., Porcelli, L., Silvestris, N., Colucci, G., Angelo, A., and Azzariti, A. (2011). EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence. Front. Biosci. 16, 1962-1972.
56. Rakhra, K., Bachireddy, P., Zabuawala, T., Zeiser, R., Xu, L., Kopelman, A., et al. (2010). CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell 18, 485-498.
57. Ramírez, B. S., Alpízar, Y. A., Fernández, D. R. H., Hidalgo, G. G., Capote, A. R., Rodríguez, R. P., et al. (2008). Anti-EGFR activation, anti-proliferative and pro-apoptotic effects of polyclonal antibodies induced by EGFR-based cancer vaccine. Vaccine 26, 4918-4926.
58. Ramírez, B. S., Pestana, E. S., Hidalgo, G. G., García, T. H., Rodríguez, R. P., Ullrich, A., et al. (2006). Active antimetastatic immunotherapy in Lewis lung carcinoma with self EGFR extracellular domain protein in VSSP adjuvant. Int. J. Cancer 119, 2190-2199.
59. Ramos-Suzarte, M., Lorenzo-Luaces, P., Lazo, N. G., Perez, M. L., Soriano, J. L., Gonzalez, C. E. V., et al. (2012). Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy. Cancer Biol. Ther. 13, 600-605.
60. Rodríguez, M. O., Rivero, T. C., Del Castillo Bahi, R., Muchuli, C. R., Bilbao, M. A., Vinageras, E. N., et al. (2010). Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol. Ther. 9, 343-349.
61. Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., et al. (2009). Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 361, 958-967.
62. Rosell, R., Taron, M., Sanchez, J. J., and Paz-Ares, L. (2007). Setting the benchmark for tailoring treatment with EGFR tyrosine kinase inhibitors. Future Oncol. 3, 277-283.
63. Saltz, L., Badarinath, S., Dakhil, S., Bienvenu, B., Harker, W. G., Birchfield, G., et al. (2012). Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer. Clin. Colorectal Cancer 11, 101-111.
64. Sato, A., Sunayama, J., Matsuda, K., Tachibana, K., Sakurada, K., Tomiyama, A., et al. (2010). Regulation of neural stem/progenitor cell maintenance by PI3K and mTOR. Neurosci. Lett. 470, 115-120.
65. Saurez, G., Cabanas, R., Zaldívar, M., Garnier, T., Iglesias, B., Piedra, P., et al. (2009). Clinical experience with nimotuzumab in cuban pediatric patients with brain tumors, 2005 to 2007. MEDICC Rev. 11, 27-33.
66. Schmitz, K. R., and Ferguson, K. M. (2009). Interaction of antibodies with ErbB receptor extracellular regions. Exp. Cell Res. 315, 659-670.
67. Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., et al. (2005). Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353, 123-132.
68. Sporn, M. B., and Todaro, G. J. (1980). Autocrine secretion and malignant transformation of cells. N. Engl. J. Med. 303, 878-880.
69. Talavera, A., Friemann, R., Gómez-Puerta, S., Martinez-Fleites, C., Garrido, G., Rabasa, A., et al. (2009). Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res. 69, 5851-5859.
70. Tol, J., Koopman, M., Cats, A., Rodenburg, C. J., Creemers, G. J. M., Schrama, J. G., et al. (2009). Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 360, 563-572.
71. Ullrich, A., Coussens, L., Hayflick, J. S., Dull, T. J., Gray, A., Tam, A. W., et al. (1984). Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309, 418-425.
72. Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., et al. (2009). Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360, 1408-1417.
73. Vermorken, J. B., Herbst, R. S., Leon, X., Amellal, N., and Baselga, J. (2008). Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies. Cancer 112, 2710-2719.
74. Viloria-Petit, A., Crombet, T., Jothy, S., Hicklin, D., Bohlen, P., Schlaeppi, J. M., et al. (2001). Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res. 61, 5090-5101.
75. Weihua, Z., Tsan, R., Huang, W.-C., Wu, Q., Chiu, C.-H., Fidler, I. J., et al. (2008). Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 13, 385-393.
76. Weinstein, I. B. (2002). Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science 297, 63-64.
77. Weinstein, I. B., and Joe, A. K. (2006). Mechanisms of disease: Oncogene addiction - a rationale for molecular targeting in cancer therapy. Nat. Clin. Pract. Oncol. 3, 448-457.
78. Weinstein, I. B., and Joe, A. K. (2008). Oncogene addiction. Cancer Res. 68, 3077-3080.
79. Weiss, G. J., Bemis, L. T., Nakajima, E., Sugita, M., Birks, D. K., Robinson, W. A., et al. (2008). EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann. Oncol. 19, 1053-1059.
80. Wright, E. M., Loo, D. D. F., and Hirayama, B. A. (2011). Biology of human sodium glucose transporters. Physiol. Rev. 91, 733-794.
81. Yan, X., Fu, C., Chen, L., Qin, J., Zeng, Q., Yuan, H., et al. (2012). Mesenchymal stem cells from primary breast cancer tissue promote cancer proliferation and enhance mammosphere formation partially via EGF/EGFR/Akt pathway. Breast Cancer Res. Treat. 132, 153-164.
82. Yarden, Y., and Pines, G. (2012). The ERBB network: at last, cancer therapy meets systems biology. Nat. Rev. Cancer 12, 553-563.
83. Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., et al. (2011). Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci. Transl. Med. 3, 99ra86.
84. Yoshikawa, S., Kukimoto-Niino, M., Parker, L., Handa, N., Terada, T., Fujimoto, T., et al. (2013). Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor. Oncogene 32, 27-38.
85. Zhang, D., LaFortune, T. A., Krishnamurthy, S., Esteva, F. J., Cristofanilli, M., Liu, P., et al. (2009). Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer. Clin. Cancer Res. 15, 6639-6648.